quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:25:19·73d
INSIDERFiling
Galectin Therapeutics Inc. logo

Director Eldred Kary bought $810 worth of shares (300 units at $2.70), increasing direct ownership by 0.46% to 65,682 units (SEC Form 4)

GALT· Galectin Therapeutics Inc.
Health Care
Original source

Companies

  • GALT
    Galectin Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jun 17UpdateH.C. Wainwright$6.00

Related

  • SEC11d
    SEC Form EFFECT filed by Galectin Therapeutics Inc.
  • SEC23d
    SEC Form S-3 filed by Galectin Therapeutics Inc.
  • PR24d
    Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
  • SEC24d
    Galectin Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • SEC24d
    SEC Form 10-K filed by Galectin Therapeutics Inc.
  • INSIDER38d
    SEC Form 4 filed by Director Brem Henry
  • INSIDER38d
    New insider Brem Henry claimed no ownership of stock in the company (SEC Form 3)
  • PR38d
    Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022